282 million people, Southeast Asia's largest population, more than 300 ethnic groups, one of the world's highest TB burdens, endemic dengue, JKN near-universal coverage, landmark Wolbachia dengue research from Yogyakarta, and highly competitive regional trial costs.
Indonesia is the world's fourth most populous country and ASEAN's largest nation; a vast archipelago of approximately 17,508 islands stretching 5,100 km from Sumatra to Papua, straddling the equator between mainland Southeast Asia and Australia. With approximately 282 million people, Indonesia's population exceeds Thailand, Malaysia, Singapore, the Philippines, Vietnam, and Myanmar combined. Jakarta anchors the national clinical research network through RSCM, affiliated with the University of Indonesia Faculty of Medicine. Yogyakarta; home of Universitas Gadjah Mada; is internationally recognised as the site of the landmark Wolbachia-Aedes dengue trial published in NEJM in 2021. Surabaya, Bandung, Semarang, Makassar, and Medan each anchor their respective island regions through university-hospital partnerships. Indonesia is a G20 member and has committed to near-universal health coverage through the JKN (Jaminan Kesehatan Nasional) scheme managed by BPJS Kesehatan.
Clinical trials are regulated by BPOM (Badan Pengawas Obat dan Makanan), Indonesia's pharmaceutical regulatory authority, which oversees clinical trial applications in alignment with ICH GCP E6(R2) and WHO GCP guidelines. Ethics review is conducted by institutional ethics committees at each research hospital, coordinated nationally by the KNEPK under the Ministry of Health. The Ministry's research arm; NIHRD (Litbangkes), now coordinated under BRIN; provides national health research coordination. JKN has enrolled approximately 260 million people (over 90% of the population), creating a structured patient identification and care pathway across Indonesia's hospital network. BPOM's regulatory modernisation program has been steadily reducing trial authorisation timelines, with ongoing investment in digital submission systems and expedited review tracks.
Indonesia's population is the most ethnically complex of any large nation in ASEAN; comprising over 300 distinct indigenous ethnic groups. Javanese (~40%), Sundanese (~15%), Batak, Minangkabau, Bugis, Madurese, and dozens of others constitute the Austronesian core. Eastern Indonesia; Papua, Maluku, and Nusa Tenggara; carries populations of Melanesian ancestral heritage that are genetically among the most distinct human populations relative to all other Indonesian groups. A Chinese Indonesian (Tionghoa) community of approximately 1.2–1.5% adds a Han Chinese pharmacogenomic dimension. Indonesia is the world's largest Muslim-majority country (~87%). English proficiency is strong among academic medical investigators; patient-facing materials require Bahasa Indonesia adaptation.
Indonesia's disease burden is shaped by the simultaneous weight of high infectious disease prevalence and rapidly accelerating non-communicable disease incidence. Tuberculosis is the defining public health challenge; Indonesia is one of the world's highest TB burden countries (after India), with approximately 800,000 to one million new cases annually; drug-resistant TB (MDR-TB) concentrated in Jakarta, Surabaya, and Bandung. Dengue fever is hyperendemic across the archipelago. Malaria persists at high rates in Papua, Maluku, and Nusa Tenggara Timur. Cardiovascular disease has become the leading cause of death as Indonesia urbanises rapidly. Type 2 diabetes affects approximately 10–11% of Indonesian adults. Cancer, HIV (concentrated in Papua and among MSM nationally), and neglected tropical diseases including leprosy, lymphatic filariasis, and focal schistosomiasis (unique to Sulawesi) complete an extraordinarily complex landscape.
The world's most clinically underrepresented large population and its most urgent research opportunity. For TB drug development, Indonesia's approximately 800,000 to one million new TB cases annually; including high-density MDR-TB concentrations in Jakarta, Surabaya, and Bandung; provide patient pools that exceed every other Southeast Asian country combined. Papua province's Melanesian-ancestry populations, combined with very high malaria intensity and elevated HIV prevalence, create a research platform for malaria pharmacology, HIV prevention, and Melanesian-ancestry pharmacogenomics that does not exist at scale anywhere else in Southeast Asia.
Indonesia's research proposition is fundamentally about scale that no ASEAN competitor can match; 282 million people, one of the world's highest TB burdens, hyperendemic dengue, one of Asia's largest diabetes populations, and genetic diversity across 300+ ethnic groups that makes Indonesian trial data pharmacogenomically richer than most single-country Asian datasets; in a market whose cost efficiency is among the region's most competitive.
BPOM aligned with ICH GCP E6(R2) and WHO GCP standards; ongoing BPOM regulatory modernisation reducing clinical trial authorisation timelines with digital submission systems; KNEPK national ethics coordination; BRIN-coordinated national research infrastructure; Ministry of Health commitment to health research investment under the National Health Research System; G20 membership driving international pharmaceutical regulatory engagement and Indonesian regulatory alignment with global standards.
Per-patient and operational costs among Southeast Asia's most competitive; comparable to Philippines and significantly below Thailand, Malaysia, Taiwan, or Singapore; investigator fees, hospital costs, and clinical research staff compensation substantially lower than regional premium markets; 282 million-person scale enabling enrollment velocity that compounds per-patient savings into major total program budget advantages; IDR favourable for USD- and EUR-denominated budgets.
World's fourth-largest population (282M); ASEAN's largest by far; creating depth across virtually every therapeutic area; high global TB burden enabling antimicrobial Phase II–III enrollment at ASEAN's highest velocity; hyperendemic dengue for infectious disease and vaccine programs; high malaria intensity in Papua for antimalarial development; one of Asia's largest T2DM populations; 300+ genetically distinct ethnic groups including Melanesian-ancestry Papuan populations unique in ASEAN; JKN ~90%+ population coverage.
RSCM (national referral hospital) and Universitas Indonesia as Jakarta research anchors; Universitas Gadjah Mada and Dr. Sardjito Hospital (Yogyakarta) as dengue research global leaders; five regionally distributed academic university hospital partnerships (Airlangga, Padjadjaran, Diponegoro, Hasanuddin, USU) providing island-spanning site network; RS Dharmais as dedicated national cancer centre; BRIN biomedical research infrastructure; World Mosquito Program dengue research platform; growing multinational CRO presence in Jakarta and Surabaya.
Infectious disease; particularly tuberculosis and dengue; is Indonesia's globally defining research pillar by both patient volume and investigator depth. Indonesia's approximately 800,000 to one million annual TB cases place it second only to India globally. Dengue's prominence carries a distinctive scientific dimension: Universitas Gadjah Mada's partnership with the World Mosquito Program produced the landmark 2021 NEJM Wolbachia trial, positioning Indonesian investigators at the frontier of dengue biological control science. Metabolic and cardiovascular disease are Indonesia's fastest-growing pillars, driven by rapid urbanisation; with 10–11% adult diabetes prevalence across 282 million people, Indonesia's T2DM patient pool is among the world's largest. Malaria in Papua, leprosy, lymphatic filariasis, and focal schistosomiasis in Sulawesi complete an infectious disease profile that includes neglected tropical diseases almost entirely absent from comparable-scale middle-income country research markets. Oncology is the most rapidly developing commercial pillar, with RS Dharmais and growing oncology departments at major university hospitals building Phase II–III infrastructure.
Jakarta's cluster of national specialty and academic hospitals; anchored by RSCM as Indonesia's national referral institution; accounts for the largest share of Phase II–III commercial trial volume, supported by RS Dharmais (oncology) and RS Persahabatan (pulmonology and TB). Yogyakarta's Dr. Sardjito Hospital and Universitas Gadjah Mada have achieved global visibility through the Wolbachia dengue research programme. Surabaya, Bandung, Semarang, Makassar, Medan, Bali, and Solo each contribute regionally through their academic university hospital partnerships.
| # | Site | City | Notes |
|---|---|---|---|
| 01 | RSCM; Dr. Cipto Mangunkusumo National General Hospital | Jakarta | Indonesia's national referral hospital and the country's primary academic research institution; Universitas Indonesia Faculty of Medicine affiliate; Phase I–IV across oncology, infectious disease (TB, dengue, HIV), haematology, cardiovascular, nephrology, neurology, and rare diseases; as the national referral centre, RSCM receives the most complex and treatment-naïve patients from across Indonesia's 34 provinces; home to Indonesia's largest Phase I unit and the primary portal for international pharmaceutical sponsors activating the Indonesian research market. |
| 02 | RS Dharmais; National Cancer Centre Indonesia | Jakarta | Indonesia's dedicated national cancer hospital, operating exclusively as an oncology treatment and research centre under the Ministry of Health; Phase II–IV across solid tumours (breast, lung, colorectal, cervical, and liver cancer), haematological malignancies, and emerging oncology modalities including immunotherapy and targeted therapies; disease-focused institutional mandate creates strong cancer-patient concentration for growing Phase II–III oncology programs. |
| 03 | RS Persahabatan; National Respiratory Hospital | Jakarta | Indonesia's nationally designated respiratory hospital; one of the largest dedicated pulmonology institutions in Southeast Asia; Phase II–IV research capability focused on tuberculosis (drug-sensitive and MDR-TB), COPD, lung cancer, pneumonia, and respiratory infectious disease; manages one of Southeast Asia's largest drug-resistant TB patient registries; Indonesia's primary site for next-generation anti-TB regimen development. |
| 04 | RSUP Dr. Sardjito | Yogyakarta | Universitas Gadjah Mada's primary academic hospital and the institutional home of the Wolbachia-Aedes aegypti dengue trial, whose 2021 NEJM results demonstrated approximately 77% reduction in dengue incidence; Phase II–IV across dengue, infectious disease, oncology, cardiovascular, and internal medicine; a key site for any sponsor developing dengue therapeutics, vaccine candidates, or biological control platform programs. |
| 05 | RSUD Dr. Soetomo | Surabaya | East Java's major academic hospital and one of Indonesia's largest public hospitals by patient volume; Airlangga University (UNAIR) Faculty of Medicine and Health affiliate; Phase II–IV across oncology, infectious disease (TB, dengue), cardiovascular, haematology, and internal medicine; serves the Surabaya metropolitan area of approximately 10 million people; strong investigator pipeline for both commercial Phase II–III and investigator-initiated trial programs. |
| 06 | RSUP Dr. Hasan Sadikin (RSHS) | Bandung | West Java's major academic hospital and the primary clinical institution for Padjadjaran University (UNPAD) Faculty of Medicine; Phase II–IV across infectious disease, oncology, cardiovascular, and internal medicine; Bandung's highland location provides geographic patient diversity within multi-site Indonesian trial designs; significant TB research site given West Java's high TB burden. |
| 07 | RSUP Dr. Kariadi | Semarang | Central Java's major academic hospital and the primary clinical institution for Diponegoro University (UNDIP) Faculty of Medicine; Phase II–IV across oncology, cardiovascular, diabetes, and infectious disease; serves the Central Java provincial catchment of approximately 37 million people; active diabetes and metabolic disease research programme. |
| 08 | RSUP Dr. Wahidin Sudirohusodo | Makassar | South Sulawesi's major academic hospital and the primary clinical institution for Hasanuddin University (UNHAS) Faculty of Medicine; Phase II–IV across infectious disease (dengue, TB, and malaria), oncology, cardiovascular, and internal medicine; established tropical medicine research tradition; provides access to focal schistosomiasis research in Central Sulawesi, the only endemic schistosomiasis focus in Indonesia. |
| 09 | RSUP H. Adam Malik | Medan | North Sumatra's major academic hospital and the primary clinical institution for Universitas Sumatera Utara (USU) Faculty of Medicine; Phase II–IV across oncology, cardiovascular, infectious disease, and internal medicine; serves the Medan metropolitan area of approximately 4 million people; North Sumatra's Batak population offers documented pharmacogenomic sub-group data of research value. |
| 10 | RSUP Prof. Dr. I.G.N.G. Ngoerah (Sanglah Hospital) | Denpasar | Bali's major academic hospital and the primary clinical institution for Udayana University (UNUD) Faculty of Medicine; Phase II–IV across infectious disease, oncology, cardiovascular, and internal medicine; Bali's international connectivity and the distinct Balinese (Hindu-majority) ethnic and cultural dimension add differentiation within Indonesia's research landscape; active dengue, HIV, and TB research. |
| 11 | RSUP Dr. Moewardi | Surakarta | Central Java's second major academic hospital, located in Surakarta (Solo), affiliated with Sebelas Maret University (UNS) Faculty of Medicine; Phase II–III across oncology, cardiovascular, metabolic disease, and internal medicine; important site for sponsors designing Java-wide trial networks that require complete provincial geographic coverage across the island that holds approximately 60% of Indonesia's total population. |
| 12 | RSUP Prof. Dr. R.D. Kandou | Manado | North Sulawesi's major academic hospital, affiliated with Sam Ratulangi University (UNSRAT) Faculty of Medicine; Phase II–III across cardiovascular, oncology, and infectious disease; a key gateway to eastern Indonesia's research catchment where Melanesian-ancestry populations begin to predominate; provides geographic proximity to Papua and Maluku disease research frontiers without fully remote logistics. |
Indonesia's national referral hospital and the country's primary academic research institution; Universitas Indonesia Faculty of Medicine affiliate; Phase I–IV across oncology, infectious disease (TB, dengue, HIV), haematology, cardiovascular, nephrology, neurology, and rare diseases; as the national referral centre, RSCM receives the most complex and treatment-naïve patients from across Indonesia's 34 provinces; home to Indonesia's largest Phase I unit and the primary portal for international pharmaceutical sponsors activating the Indonesian research market.
Indonesia's dedicated national cancer hospital, operating exclusively as an oncology treatment and research centre under the Ministry of Health; Phase II–IV across solid tumours (breast, lung, colorectal, cervical, and liver cancer), haematological malignancies, and emerging oncology modalities including immunotherapy and targeted therapies; disease-focused institutional mandate creates strong cancer-patient concentration for growing Phase II–III oncology programs.
Indonesia's nationally designated respiratory hospital; one of the largest dedicated pulmonology institutions in Southeast Asia; Phase II–IV research capability focused on tuberculosis (drug-sensitive and MDR-TB), COPD, lung cancer, pneumonia, and respiratory infectious disease; manages one of Southeast Asia's largest drug-resistant TB patient registries; Indonesia's primary site for next-generation anti-TB regimen development.
Universitas Gadjah Mada's primary academic hospital and the institutional home of the Wolbachia-Aedes aegypti dengue trial, whose 2021 NEJM results demonstrated approximately 77% reduction in dengue incidence; Phase II–IV across dengue, infectious disease, oncology, cardiovascular, and internal medicine; a key site for any sponsor developing dengue therapeutics, vaccine candidates, or biological control platform programs.
East Java's major academic hospital and one of Indonesia's largest public hospitals by patient volume; Airlangga University (UNAIR) Faculty of Medicine and Health affiliate; Phase II–IV across oncology, infectious disease (TB, dengue), cardiovascular, haematology, and internal medicine; serves the Surabaya metropolitan area of approximately 10 million people; strong investigator pipeline for both commercial Phase II–III and investigator-initiated trial programs.
West Java's major academic hospital and the primary clinical institution for Padjadjaran University (UNPAD) Faculty of Medicine; Phase II–IV across infectious disease, oncology, cardiovascular, and internal medicine; Bandung's highland location provides geographic patient diversity within multi-site Indonesian trial designs; significant TB research site given West Java's high TB burden.
Central Java's major academic hospital and the primary clinical institution for Diponegoro University (UNDIP) Faculty of Medicine; Phase II–IV across oncology, cardiovascular, diabetes, and infectious disease; serves the Central Java provincial catchment of approximately 37 million people; active diabetes and metabolic disease research programme.
South Sulawesi's major academic hospital and the primary clinical institution for Hasanuddin University (UNHAS) Faculty of Medicine; Phase II–IV across infectious disease (dengue, TB, and malaria), oncology, cardiovascular, and internal medicine; established tropical medicine research tradition; provides access to focal schistosomiasis research in Central Sulawesi, the only endemic schistosomiasis focus in Indonesia.
North Sumatra's major academic hospital and the primary clinical institution for Universitas Sumatera Utara (USU) Faculty of Medicine; Phase II–IV across oncology, cardiovascular, infectious disease, and internal medicine; serves the Medan metropolitan area of approximately 4 million people; North Sumatra's Batak population offers documented pharmacogenomic sub-group data of research value.
Bali's major academic hospital and the primary clinical institution for Udayana University (UNUD) Faculty of Medicine; Phase II–IV across infectious disease, oncology, cardiovascular, and internal medicine; Bali's international connectivity and the distinct Balinese (Hindu-majority) ethnic and cultural dimension add differentiation within Indonesia's research landscape; active dengue, HIV, and TB research.
Central Java's second major academic hospital, located in Surakarta (Solo), affiliated with Sebelas Maret University (UNS) Faculty of Medicine; Phase II–III across oncology, cardiovascular, metabolic disease, and internal medicine; important site for sponsors designing Java-wide trial networks that require complete provincial geographic coverage across the island that holds approximately 60% of Indonesia's total population.
North Sulawesi's major academic hospital, affiliated with Sam Ratulangi University (UNSRAT) Faculty of Medicine; Phase II–III across cardiovascular, oncology, and infectious disease; a key gateway to eastern Indonesia's research catchment where Melanesian-ancestry populations begin to predominate; provides geographic proximity to Papua and Maluku disease research frontiers without fully remote logistics.
These are the primary regulatory, academic, and industry bodies shaping Indonesia's clinical research ecosystem.
Indonesia's national pharmaceutical regulatory authority and the competent body for clinical trial authorization; regulatory framework aligned with ICH GCP E6(R2) and WHO GCP standards; ongoing modernisation of digital submission processes and review timelines; active participant in ASEAN pharmaceutical regulatory harmonisation.
Oversees Indonesia's national health research policy through Litbangkes / NIHRD (now coordinated under BRIN) and maintains the KNEPK national ethics committee system; JKN Universal Health Coverage has enrolled approximately 260 million Indonesians, creating structured patient identification and care pathway infrastructure.
Indonesia's national research coordination body, consolidating LIPI, BPPT, and the Eijkman Institute for Molecular Biology; coordinates biomedical, genomics, and health research infrastructure across Indonesian universities and government research institutions; supports pharmacogenomics analytical capacity.
Indonesia's premier medical faculty, affiliated with RSCM and driving the national investigator pipeline across infectious disease, oncology, cardiovascular medicine, and pharmacology; most internationally connected Indonesian academic medical institution with established WHO, NIH, and pharma partnerships.
Yogyakarta's premier university and institutional partner in the World Mosquito Program's landmark Wolbachia dengue trial (2021 NEJM); leading dengue, TB, and community-based infectious disease research programme; Indonesia's most scientifically ambitious regional research university for infectious disease programs.
The Ministry of Health's health research agency, now coordinated within BRIN; operates the RISKESDAS national health surveys used for trial feasibility assessments; manages national health research ethics coordination through KNEPK.
Surabaya's major medical faculty, affiliated with RSUD Dr. Soetomo and driving the East Java investigator pipeline; internationally active in dengue, TB, and tropical disease research; growing pool of internationally trained clinical investigators for commercial Phase II–III program partnerships.
Global CRO with significant Indonesian operations managing Phase II–IV programs across infectious disease (TB, dengue), oncology, metabolic disease, and cardiovascular indications; BPOM regulatory submission expertise; established site monitoring presence at RSCM, RS Dharmais, RS Persahabatan, Dr. Sardjito, and Dr. Soetomo Hospital.
International CRO with Indonesian operations supporting Phase II–IV oncology, infectious disease, metabolic disease, and cardiovascular programs; established investigator relationships across national hospitals; specialist TB and dengue trial management capability reflecting Indonesia's disease profile.
Global CRO with Indonesian operations providing Phase II–III trial management, regulatory strategy, and data management; BPOM submission expertise; established site networks across Jakarta national hospitals and regional university hospitals in Surabaya, Yogyakarta, and Bandung.
Nonprofit research program that partnered with Universitas Gadjah Mada for the landmark Yogyakarta Wolbachia dengue trial (2021 NEJM, ~77% dengue case reduction); continues to operate in Indonesia as a clinical and public health research partner for dengue prevention, surveillance, and intervention programs.
Indonesia is ASEAN's most populous clinical research frontier; a country whose 282 million people, one of the world's highest TB burdens, and hyperendemic dengue create research patient pools no other Southeast Asian nation can approach by scale, while its ethnic diversity across 300+ groups and 17,000 islands adds pharmacogenomic richness that makes Indonesian trial data uniquely informative. Approximately 800,000 to one million new TB cases annually enables Phase III antimicrobial enrollment at velocities no other single ASEAN country matches. Universitas Gadjah Mada's Wolbachia dengue trial placed Indonesian investigators at the scientific frontier of dengue research. Indonesia's diabetes trajectory; 10–11% adult prevalence across 282 million people; will create one of the world's largest T2DM and obesity research markets within the current decade. The gap between Indonesia's research potential and its current trial representation is closing, driven by BPOM's regulatory modernisation, BRIN's research infrastructure consolidation, and the growing international recognition that no serious Asia-Pacific clinical development strategy is complete without Indonesia engaged as a research partner.
Keep exploring
Discover 11 early-phase clinical trials and design frameworks redefining development strategy in 2025-2026, and what sponsors can learn to reduce late-stage failure risk.
Four pervasive AI misconceptions in clinical trials that derail programs, inflate costs, and create regulatory exposure, with evidence on what the data actually shows.
Before selecting an AI patient screening tool for clinical trial recruitment, ask these 7 critical questions to avoid costly mismatches and protocol failures.
Accelerated Approval is an FDA pathway that allows earlier approval of drugs treating serious conditions and filling unmet medical need on the basis of a surrogate endpoint that is reasonably likely to predict clinical benefit, conditional on confirmatory post-marketing trials.